Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
detroit blog main
detroit top stories
8
×
fda
life sciences
national blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
national
cancer
drugs
eli lilly
amgen
calcitonin gene-related peptide
deals
eptinezumab
erenumab
fremanezumab
galcanezumab
medical device
What
drug
8
×
fda
8
×
approved
approval
new
won
bio
cancer
class
companies
developed
drugs
medicine
medicines
migraine
news
nod
oral
patients
roundup
second
therapeutics
therapy
time
agency
aimmune
allergy
amgen
aren’t
arguments
awarded
big
candidates
cholesterol
combo
commercialized
competitors
decades
deeper
developers
Language
unset
Current search:
drug
×
fda
×
" detroit top stories "
×
@xconomy.com
4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines